A pharmaceutical formulation is provided for delivering paclitaxel in vivo
comprising: paclitaxel, a water-miscible amide and a
pharmaceutically-acceptable, water-miscible solubilizer selected from the
group consisting of solubilizers having the general structures
R.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, and R.sub.1 COR.sub.2,
wherein R.sub.1 is a hydrophobic C3-C50 alkane, alkene or alkyne and
R.sub.2 is a hydrophilic moiety.
Um formulation pharmaceutical é fornecido entregando o paclitaxel em compreender de vivo: o paclitaxel, um amido water-miscible e um solubilizer pharmaceutically-acceptable, water-miscible selecionados dos solubilizers consistindo do grupo que têm o general estruturam R.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, e R.sub.1 COR.sub.2, wherein R.sub.1 são um alkane C3-C50 hydrophobic, alkene ou o alkyne e R.sub.2 é um moiety hydrophilic.